About Biocon limited

Biocon Limited, publicly listed in 2004, is India’s largest and fully-integrated,

innovation-led biopharmaceutical company. As an emerging global
biopharmaceutical enterprise serving customers in over 100 countries, it is
committed to reduce therapy costs of chronic diseases like autoimmune,
diabetes, and cancer. Through innovative products and research services it
is enabling access to affordable healthcare for patients, partners and
healthcare systems across the globe. It has successfully developed and
taken a range of Novel Biologics, Biosimilars, differentiated Small
Molecules and affordable Recombinant Human Insulin and Analogs from
‘Lab to Market’.
Vision and Mission
To enhance global healthcare through innovative and affordable
biopharmaceuticals for patients, partners and healthcare systems across
the globe. To become a recognized center for advanced learning in
Biosciences that will provide the required proficiency for enhanced career
prospects for Biotechnology and Engineering graduates.
To be an integrated biotechnology enterprise of global distinction.

MISSION--- Essential to this mission is excellence in:

– Intellectual asset creation through discovery, research and   development

– State-of-the-art manufacturing capabilities

– Internationally benchmarked quality and regulatory systems

– New medical insight through disease specific

clinical research

– Customer relationship through outstanding products

and services

– Human resource development through training,

mentoring and empowering

– Management of research and business partnerships

Business Strategy
he business model of Biocon consists of five key growth verticals – Small Molecules
(APIs),Biosimilars, Branded Formulations, Novel Molecules and Research Services.
All the five verticals are integrated for growth of the company and also help to cut
the competition.

Biocon’s strategy is focused on expanding its presence in the rapidly growing

emerging markets through strong regional partnerships.Biocon’s fully integrated
business model span the entire value chain from preclinical discovery to clinical
development and through the commercialization strategy.
Company focuses on the innovation, Brand building and go to consumer tactics for
their strong presence among the Pharma and Biotechnology companies across the
world. Three divisions – Syngene, Clingene and Biocon are the backbone of the
company and are engaged pre clinical, clinical and commercialization divisions
respectively. When Syngene do the preclinical discoveries which is a full on
innovation strategy, the next level is early phase discovery that is executed by the
clinical research team of Clingene. Then the process scale-up processes are done in
the commercialize division. Hence, there is a chain process which is followed to add
value at each level of the chain.This unique integrated innovation approach has
yielded lots of products and technologies that have enabled multi level relationships
with global parterners.
Corecompetencies:
There are certain areas which define the core competency of Biocon, here are some
listed competencies of the company:
* Unique fermentation base
* Research and Development excellence
* Manufacturing Excellence – flexibility in the product mix and meeting the higher
standards of quality.
* Strong customer relationships
* Depth of management and Ability to attract new talents.